220 related articles for article (PubMed ID: 17547976)
21. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia.
Vasconcelos S; Birkent H; Sardesai MG; Merati AL; Hillel AD
Laryngoscope; 2009 Oct; 119(10):2004-7. PubMed ID: 19572275
[TBL] [Abstract][Full Text] [Related]
22. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
23. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results.
Paniello RC; Barlow J; Serna JS
Laryngoscope; 2008 Mar; 118(3):564-8. PubMed ID: 18216744
[TBL] [Abstract][Full Text] [Related]
25. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
Kuo HC
Urology; 2006 Nov; 68(5):993-7; discussion 997-8. PubMed ID: 17113890
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of a portable, audible-only electromyography device in the treatment of spasmodic dysphonia.
Jeffcoat BT; Schweinfurth JM
Laryngoscope; 2008 May; 118(5):942-3. PubMed ID: 18197130
[No Abstract] [Full Text] [Related]
27. The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.
Buchholz DW; Neumann S
Dysphagia; 1997; 12(1):59-60. PubMed ID: 8997837
[No Abstract] [Full Text] [Related]
28. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults.
Ekbom DC; Garrett CG; Yung KC; Johnson FL; Billante CR; Zealear DL; Courey MS
Laryngoscope; 2010 Apr; 120(4):758-63. PubMed ID: 20213793
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
[TBL] [Abstract][Full Text] [Related]
30. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
Adams SG; Hunt EJ; Charles DA; Lang AE
J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
[TBL] [Abstract][Full Text] [Related]
31. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate.
Kwon JS; Kim ST; Jeon YM; Choi JH
Int J Oral Maxillofac Surg; 2009 Apr; 38(4):316-20. PubMed ID: 19231136
[TBL] [Abstract][Full Text] [Related]
32. Long-term botulinum toxin efficacy, safety, and immunogenicity.
Mejia NI; Vuong KD; Jankovic J
Mov Disord; 2005 May; 20(5):592-7. PubMed ID: 15645481
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
[TBL] [Abstract][Full Text] [Related]
34. Comparison between intramuscular and perimuscular injections of botulinum toxin type A.
Campos JH; Oliveira LB; Queiroz TO; Santos KP; Freitas FM
Aesthetic Plast Surg; 2006; 30(6):700-3; discussion 704. PubMed ID: 16977369
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.
Hamdy RC; Montpetit K; Raney EM; Aiona MD; Fillman RR; MacKenzie W; McCarthy J; Chafetz RS; Thomas SS; Tamayo CM; Littleton AG; Ruck-Gibis J; Takahashi SN; Rinaldi M; Finley GA; Platt RW; Dahan-Oliel N
J Pediatr Orthop; 2009; 29(5):427-34. PubMed ID: 19568011
[TBL] [Abstract][Full Text] [Related]
37. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin.
Levy JL; Pons F; Jouve E
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):711-6. PubMed ID: 16836501
[TBL] [Abstract][Full Text] [Related]
38. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
Cha W; Jang JY; Wang SG; Kang JH; Jo MG
J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
[TBL] [Abstract][Full Text] [Related]
39. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia.
Maloney AP; Morrison MD
J Otolaryngol; 1994 Jun; 23(3):160-4. PubMed ID: 8064952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
